Figure 1: Improved phenotype and functionality of mDCs and pDCs in Peripheral blood among patients receiving monotherapy and sequential therapy. (A-B) No significant increase in frequencies of mDCs and pDCs was observed after 24weeks of both therapies. (C-D) Expression of co-stimulatory molecules was analyzed after 24week of each therapy. No significant difference was observed with both therapies. (E-F) In between two therapies, sequential therapy increased the HLA-DR expression on mDCs and pDCs and CD83 expression on pDCs. (G-H) With TLRs agonist stimulations, in sequential therapy mDCs and pDCs showed significantly increased expression of TLRs. Results were expressed as the mean and error bars represent SD.